Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults

Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults

Show other versions (1)

Bibliographic Details
Main Authors:	Inés Mendoza, Alicia Lázaro, Alfredo Espinosa, Lorenzo Sánchez, Ana María Horta, Miguel Torralba
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2023-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540944/?tool=EBI

Similar Items

Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
by: Inés Mendoza, et al.
Published: (2023-01-01)

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
by: Hernando Knobel, et al.
Published: (2023-07-01)

Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1
by: Yinghua Wei, et al.
Published: (2023-11-01)

Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV
by: Giuseppe Vittorio De Socio, et al.
Published: (2023-12-01)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study
by: Lin Gan, et al.
Published: (2023-10-01)

Bictegravir, Emtricitabine & Tenofovir Alafenamide-associated Acute Pancreatitis
by: Abdulmajeed Alharbi
Published: (2023-05-01)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice
by: Canetti D, et al.
Published: (2023-12-01)

Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?
by: Januszka JE, et al.
Published: (2023-11-01)

Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China
by: Cao Jing, et al.
Published: (2023-06-01)

Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide
by: Franco Maggiolo, et al.
Published: (2022-11-01)

Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)
by: Anna Gidari, et al.
Published: (2023-12-01)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
by: Inès Devred, et al.
Published: (2023-09-01)

Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide
by: Jen-Yu Hsu, et al.
Published: (2024-03-01)

Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV
by: Baptiste Sellem, et al.
Published: (2023-03-01)

Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide
by: Ling-Ya Chen, et al.
Published: (2023-06-01)

Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
by: Yongquan Peng, et al.
Published: (2023-11-01)

Clinical efficacy, safety, and subjective experience based on ePRO in HIV‐infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China
by: Linghong Kong, et al.
Published: (2023-08-01)

Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trialsResearch in context
by: Paul E. Sax, et al.
Published: (2023-05-01)

Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
by: Claudia E Frola, et al.
Published: (2023-01-01)

Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study
by: Monica Basso, et al.
Published: (2023-08-01)

Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation
by: Mao-Song Tsai, et al.
Published: (2023-01-01)

Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies
by: Mark Underwood, et al.
Published: (2024-03-01)

Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice
by: Daniele Armenia, et al.
Published: (2022-09-01)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study
by: Javier Perez Stachowski, et al.
Published: (2022-08-01)

Assessment of treatment outcomes for HIV Positives transitioned from Tenofovir/Lamivudine/Efavirenz to Tenofovir/Lamivudine/Dolutegravir in a Nigerian Tertiary Hospital
by: Omobola Yetunde Ojo, et al.
Published: (2023-12-01)

An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1
by: An Liu, et al.
Published: (2022-11-01)

Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies
by: Mounir Ait-Khaled, et al.
Published: (2021-12-01)

The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review
by: Aprilianti S, et al.
Published: (2024-01-01)

Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort
by: Alessandro Lazzaro, et al.
Published: (2023-05-01)

Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
by: Allison Martin, et al.
Published: (2011-01-01)

Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1
by: Donga P, et al.
Published: (2023-07-01)

Increased human immunodeficiency virus viral load with cerebral infarction due to varicella zoster virus vasculopathy on treatment with bictegravir/emtricitabine/tenofovir alafenamide suspension: a case report and literature review
by: Kazuhiro Ishikawa, et al.
Published: (2023-07-01)

Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis
by: Keith Dunn, et al.
Published: (2021-07-01)

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study
by: Bruce Rashbaum, et al.
Published: (2019-01-01)

A Comparison between the Efficiency of Vonavir (Tenofovir-Emtricitabine- Efavirenz) and Cobavir (Lamivudine-Zidovudine) with Efavirenz used for HIV Patients in Fasa, Iran
by: Saeideh Honarmand, et al.
Published: (2022-07-01)

Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe
by: Vinie Kouamou, et al.
Published: (2023-09-01)

Effectiveness of tenofovir/emtricitabine versus zidovudine/lamivudine in combination with efavirenz in antiretro viral-naive HIV infected patients / Siti Mahanim Shaik Ismail
by: Shaik Ismail, Siti Mahanim
Published: (2015)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen
by: Keene, CM, et al.
Published: (2021)

Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients
by: Yu-Shan Huang, et al.
Published: (2023-06-01)